Covid-19 in Germany: Berlin prepares for mass vaccination
The vaccine developed by BioNTech could be available as early as December.
Justin Tallis AFP
Text by: RFI Follow
2 min
The German authorities want to be ready on time if BioNtech's promise to deliver its Covid-19 vaccine as early as December is kept.
The different regions are working hard to set up vaccination centers.
Publicity
Read more
With our correspondent in Berlin,
Pascal Thibaut
In Berlin, the Covid-19 hospital mounted quickly in the spring had remained unused since.
A specialist in humanitarian missions abroad, Albrecht Broemme must now prepare for the vaccination of 450,000 Berliners there.
Everything must be ready by mid-December in case
the vaccine prepared by the German company BioNtech with the American Pfizer is already available.
“
We have to try
20,000
vaccinations a day,” he
explains.
The plan is for this to last about 1h15 for each person.
Two vaccinations should be given for each person.
When it starts in the middle of December, it will only last two months.
But afterwards, the vaccinations are given by the doctors.
"
The most vulnerable and medical personnel first
General practitioners are not in the running at first because only the most vulnerable people and medical staff will be vaccinated.
In addition, the BioNtech-Pfizer vaccine must be stored at -75 ° C, which involves special refrigerators.
The vaccination centers will be open seven days a week, from 9 a.m. to 7 p.m.
Staff will still have to be found: retired nurses, medical students, hostesses and security guards.
In total, 300 people have already spontaneously offered their services.
► (Re) listen: Researchers mobilized against Covid-19
Newsletter
Receive all the international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_FR
Germany
Health and medicine
Coronavirus
On the same subject
European accents
Researchers mobilized against Covid-19
Covid-19: Germany extends and strengthens its health measures
BioNTech: the resounding success of a couple of researchers